Mode
Text Size
Log in / Sign up

Hepatitis E vaccine linked to elevated spontaneous abortion risk when given 31-60 days before pregnancy

Hepatitis E vaccine linked to elevated spontaneous abortion risk when given 31-60 days before pregna…
Photo by CDC / Unsplash
Key Takeaway
Interpret the association between HEV239 and spontaneous abortion as observational; no biological mechanism was found.

This randomized controlled trial analyzed spontaneous abortion (SAB) risk in women who received the Hepatitis E vaccine (HEV239) or Hepatitis B vaccine (HBV) during or within 90 days before pregnancy. The primary outcome was SAB, with secondary outcomes including maternal risk profiles, gestational age at SAB, and short-term adverse reactions.

Baseline maternal risk factors for SAB were similar between groups. The median gestational age at SAB was comparable (HEV239: 10.5 weeks, HBV: 11 weeks; p=0.783). The key finding was an elevated risk of SAB in HEV239 recipients vaccinated 31-60 days pre-last menstrual period (Relative Risk 4.3, 95% CI 1.3-19.3, p=0.026).

Safety data from HEV239 recipients who experienced SABs showed pain in 9% and fever in 2%, rates similar to those who did not have SABs. The authors note analyses did not uncover associations pointing to a biological mechanism.

This evidence reports an association, not causation. The finding of elevated risk in a specific pre-conception window requires confirmation, and the authors call for targeted studies such as placental examinations. Clinical relevance remains uncertain pending further investigation.

Study Details

Study typeRct
EvidenceLevel 2
Follow-up2.4 mo
PublishedJan 2026
View Original Abstract ↓
BACKGROUND: A recent randomized trial of Hepatitis E Vaccine (HEV239) found an elevated risk of spontaneous abortion (SAB) in women given HEV239 during or within ninety days before pregnancy. Here we present additional analyses to better understand this risk. METHODS: We investigated whether maternal risk profiles of SAB or gestational age at SAB differed between women receiving HEV239 versus control Hepatitis B vaccine (HBV). We also assessed whether HEV239-vaccinated women who experienced SABs had distinct short-term adverse reactions compared to HEV239-vaccinated women who had live births, exploring potential inflammatory mechanisms. Finally, we assessed maternal exposure to HEV239 in narrowly defined pre-last menstrual period (LMP) windows to more precisely demarcate pre-LMP at which HEV-239 vaccination was associated with an elevated risk of SAB. Chi-square tests and Mann-Whitney U tests were performed for bivariate comparisons. Poisson models were used for multivariable analyses. FINDINGS: Baseline maternal risk factors for SAB (age, body mass index, parity, and histories of SAB, hypertension, or diabetes) were similar between the SABs in HEV239 and HBV groups. Median gestational age at SAB was comparable (10.5 weeks [IQR 10-13] for HEV239 vs. 11 weeks [IQR 9-12.2] for HBV, p = 0.783). No increased short-term adverse events (pain: 9% vs. 9%; fever: 2% vs. 1%) were observed among HEV239 recipients who experienced SABs compared to those who did not. An elevated risk of SAB was observed in HEV239 recipients vaccinated 31-60 days pre-LMP (Relative Risk 4.3 [95% CI 1.3-19.3], p = 0.026). INTERPRETATION: Our analyses did not uncover associations pointing to a biological mechanism underlying the original observation of an increased SAB rate connected to HEV239 vaccination shortly before or during pregnancy. Targeted studies such as placental examinations and genetic testing are needed to investigate potential mechanisms.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.